Medical/Pharmaceuticals

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ -- Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, Emercell SAS, has received Investigational Medicinal Product Dossier (IMPD) approval from the ...

2025-04-22 14:00 2724

Docquity and AstraZeneca's Patient Support Program Educates Tens of Thousands in Thailand

* OAZisCare, digitally powered by DocquityCare, has advanced patient education and adherence for cancer care and RSV vaccines since 2024 * The collaboration helps tackle Southeast Asia's healthcare needs, with 85.7% of doctors noting immunization rates could improve with patient support (Do...

2025-04-22 11:00 5834

Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations

HONG KONG, April 22, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year endedDecember 31, 2024 ("the Year"), demonstratin...

2025-04-22 09:00 5167

FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA

CARDIFF-BY-THE-SEA, Calif., April 22, 2025 /PRNewswire/ -- Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of$40 million in Series A financing. The round includes $20 million in new capital and the conversion of $20 million i...

2025-04-22 08:02 2531

Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange

SHANGHAI, April 22, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong...

2025-04-22 07:45 2749

The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies

PROVIDENCE, R.I., April 21, 2025 /PRNewswire/ -- EpiVax, Inc. announces a new study published inFrontiers in Immunology unveiling the impact of peptides known as "Tregitopes" on antibody maturation during immune response. Lymph nodes contain antibodies that undergo changes to their sequence as th...

2025-04-21 21:06 3533

Kelun-Biotech's novel ADC drug SKB518 has been granted the clearance of IND from the United States Food and Drug Administration (FDA)

CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical study of its potential first-in-class innovative ADC ...

2025-04-21 20:10 4539

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension

SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT), has been approved byChi...

2025-04-21 19:00 4603

Connecting Care With Clicks Announces Partnership with Prince Court Medical Center and 8 CPD Points for HCPs

KUALA LUMPUR, Malaysia, April 21, 2025 /PRNewswire/ -- Ahead of Connecting Care With Clicks 2025, Medical Channel Asia (MCA) has unveiled an expanded speaker lineup and announced Prince Court Medical Centre as the event's official Healthcare Professional (HCP) En...

2025-04-21 17:42 3206

Asia's First Real-World ctDNA-MRD Study Strengthens Evidence for Cost-Effective Cancer Monitoring

A landmark study recently published in March 2025 by JCO Oncology Advances, demonstrates the potential ofK-TRACKTM in monitoring treatment response and assessing recurrence risk among 623 Solid-Tumor Patients of six cancer types (lung, colorectal, bre...

2025-04-19 19:45 7358

Innovation and Collaboration: Advancing China's Blood Purification Industry

LIUYANG, China, April 19, 2025 /PRNewswire/ -- On April 19, 2025, the Blood Purification Professional Committee (BPPC) of the China Medical Device Industry Association (CMDIA) gathered in Liuyang,Hunan, for its annual conference, themed "Synergy and Endless Innovation." This pivotal event united ...

2025-04-19 14:30 4906

Declaration on longevity and precision medicine launched at Abu Dhabi Global Health Week

* Establishing actionable frameworks to advance precision medicine and longevity science * The declaration highlights the impact longevity and precision medicine can have on supporting healthy communities, and engages leaders to work towards actionable solutions, drive consensus among global ...

2025-04-19 01:12 4892

VISTA Eye Specialist and Tzu Chi Malaysia Continue Their Mission to Restore Sight for Underprivileged

PETALING JAYA, Malaysia, April 18, 2025 /PRNewswire/ -- In a heartfelt continuation of their mission to serve the underserved,VISTA Eye Specialist (VISTA) andTzu Chi Malaysia (Tzu Chi) have once again partnered to restore sight for the underprivileged through their second100 Cataract Surgery Prog...

2025-04-18 08:00 4160

ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone

Showcasing at ASCRS 2025: * More than 2 million cases planned with ZEISS VERACITY Surgery Planner: Growing use of one of the leading digital planning solutions for cataract surgery in the U.S. is a testament to the increased adoption of the ZEISS Cataract Workflow digital solutions by surgeons...

2025-04-17 21:00 3204

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

SHANGHAI, April 17, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day themed "Collaborate to Create," gathering senior executives, experts, and industry leaders to discuss R&D advances, strategic planning, and cutting-edge therapies. The event attracted hundreds from academia, i...

2025-04-17 16:07 6145

World Hemophilia Day 2025 - April 17, 2025 - "Access for all: Women and girls bleed too"

MONTREAL, April 17, 2025 /PRNewswire/ -- On April 17, 2025, the global bleeding disorders community will come together under the theme "Access for all: Women and girls bleed too" and celebrate World Hemophilia Day. Today, women and girls with bleeding disorders (WGBDs) are still underdiagnosed an...

2025-04-17 13:00 2681

Brain Navi Begins IPO Counseling with First Securities Inc., Setting the Stage for Global MedTech Expansion

ZHUBEI, April 17, 2025 /PRNewswire/ -- Brain Navi Biotechnology Co., Ltd. (" Brain Navi") has officially begun IPO counseling with First Securities Inc., marking a strategic step toward accessing the capital markets and advancing its long-term growth in the surgical robot technology industry.

2025-04-17 12:10 4514

Duke-NUS and T Cells Diagnostics team up to simplify T-cell analysis

* Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and management of human infectious diseases. SINGAPORE, April 17, 2025 /PRNewswire/ -- T Cell Diagnostics Pte. Ltd. ("TCD") has licensed an intellectual property (IP) and its relat...

2025-04-17 11:05 4199

Herbalgy Unveils Touch Cool Campaign at MTR* advertising: An Immersive Installation Fusing Pain Relief with Sustainability and Innovative Design

Download high-resolution images:    https://cutt.ly/srswmUXq HONG KONG, April 17, 2025 /PRNewswire/ -- Herbalgy Pharmaceutical Ltd. is pleased to unveil its latest public engagement initiative at MTR* advertising, the leading outdoor media plat...

2025-04-17 10:00 3601

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

* IFINWIL®: now TGA registered in Australia * Children diagnosed with neuroblastoma are on average just 2 years old2 * The average survival rate of children with HRNB is only 50%2 UXBRIDGE, England, April 17, 2025 /PRNewswire/ -- Norgine is pleased to announce that the Australian Therapeutic...

2025-04-17 08:01 2708
1 ... 105106107108109110111 ... 381